Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines

Figure 2

Platelet extracts counteract the inhibitory effects of Sorafenib. A representative Western blot of 2.5 μM Sorafenib action that inhibits RAF/MEK/ERK signaling in Hep3B cells (to the left of the figure). The same action had been observed by Regorafenib (data not shown). The presence of hPL from 3.75 × 107 platelets reduced drug effects (to the right) with an increase of P-ERK, P-p38, P-STAT3, consistent with the induction of cell proliferation. No changes were observed in the phosphorylation levels of JNK.

Back to article page